By Fineline Cube 
China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced this week a strategic collaboration for the development of investigational drug TEV-56278. Under the agreement, Fosun Pharma secures exclusive rights to develop, manufacture, and commercialize TEV-56278 in China (including Hong Kong, Macau, and Taiwan) and certain Southeast Asian countries, with the goal of accelerating clinical data development. Teva retains the rights to the drug in all other global markets. No financial details were disclosed.
TEV-56278 and Technology
TEV-56278 is an anti-PD1-IL2 fusion protein developed using Teva’s proprietary ATTENUKINE technology. This innovative approach enables selective delivery of IL-2 to PD-1-positive T cells, enhancing T cell anti-tumor activity while minimizing off-target systemic toxicity.
Clinical and Efficacy Profile
The candidate molecule demonstrates potential for high efficacy with reduced toxicity across multiple immuno-oncology indications. Currently in Phase I clinical trials, TEV-56278 is being evaluated for various cancer types, including melanoma.-Fineline Info & Tech